Diagnostic enteral gastrointestinal radiopaque human prescription drugs class labeling guideline for professional labeling. Final report
Technical Report
·
OSTI ID:5504711
The Food and Drug Administration (FDA) announces the availability of a class labeling guideline for the professional labeling of diagnostic enteral gastrointestinal radiopaque agents. Class labeling is appropriate for these products because they are all closely related in chemical structure, pharmacology, therapeutic activity, and adverse reactions. The guideline is intended to promote the use of identical professional labeling for each member of the diagnostic enteral gastrointestinal radiopaque drug class.
- Research Organization:
- National Center for Drugs and Biologics, Rockville, MD (USA)
- OSTI ID:
- 5504711
- Report Number(s):
- PB-83-251041
- Country of Publication:
- United States
- Language:
- English
Similar Records
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
The validation of an invitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions
Exploring adverse drug events at the class level
Journal Article
·
Fri Mar 01 00:00:00 EST 2019
· BMC Bioinformatics
·
OSTI ID:5504711
+10 more
The validation of an invitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions
Journal Article
·
Tue Jun 15 00:00:00 EDT 2010
· Toxicology and Applied Pharmacology
·
OSTI ID:5504711
+4 more
Exploring adverse drug events at the class level
Journal Article
·
Fri May 01 00:00:00 EDT 2015
· Journal of Biomedical Semantics
·
OSTI ID:5504711